ClinicalTrials.gg
RecruitingNCT05566002AIPHYUpdated Oct 22, 2026

Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension

An observational study in Pulmonary Hypertension and Pulmonary Arterial Hypertension, sponsored by Chinese Pulmonary Vascular Disease Research Group. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's listed conditions name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Chinese Pulmonary Vascular Disease Research Group · Observational

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.
Updated Oct 22, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 76 studies in Pulmonary Arterial Hypertension with a site in China — 19 open to participants now, 24 under way, 3 of them phase 3. Pulmonary Arterial Hypertension · China.

Planned enrollment
5th of 20
2,000 · median 495
Started
2022
with 7 others
Observational
20 of 76
10 open now
Primary completion
2028-12
later than 17 of 23 live
Registered
56th of 76
by date
Lead sponsor
4 of 76
Chinese Pulmonary Vascular Disease Research Group

Among the 76 studies in Pulmonary Arterial Hypertension with a site in China, this one is the 5th largest by planned enrollment of the 20 observational ones that give a count, is one of 8 that started in 2022, is one of 20 observational ones, reaches primary completion later than 17 of the 23 other live ones, and was the 56th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

19 of the 76 studies in Pulmonary Arterial Hypertension with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Pulmonary Arterial Hypertension with a site in China, or all of them as a file.
02

Study summary

Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.

Read the detailed description

Patients with pulmonary hypertension (PH) represent a challenging and heterogeneous cohort with high morbidity and mortality if left untreated. To make a definitive diagnosis of PH, one needs to conduct an invasive right heart catheterization (RHC) in order to assess the mean pulmonary artery pressure (mPAP). As PH occurs sporadically in various medical conditions, including connective tissue disease, and congenital heart disease, and presenting symptoms are non-specific, there is a need to raise the suspicion of PH early in the community. For this reason, noninvasive tools that are widely available for upfront screening would be ideal to enable timely diagnosis of PH. Transthoracic echocardiography has emerged as the mainstay for screening of PH, yet the sensitivity and specificity of this approach remain limited even in experienced hands. As high-throughput technologies advance and access to PH big data improve, it will be critical to prudently select artificial intelligence approaches for data analysis, visualization, and interpretation. By combining the multimodal clinical data (such as indicators from chest X-ray, electrocardiography, and echocardiography), this study aims to develop artificial intelligence-assisted programs to assist the screening and diagnosis of PH, and to evaluate its diagnostic accuracy for PH as compared with RHC, and to estimate whether this approach outperforms the conventional echocardiographic method.

03

Conditions studied

  • Pulmonary Hypertension
  • Pulmonary Arterial Hypertension

Browse trials for

Keywords

  • pulmonary hypertension
  • pulmonary vascular disease
  • right heart catheterization
  • echocardiography
  • electrocardiography
  • chest X-ray
  • artificial intelligence
  • machine learning
  • deep learning
  • screening
  • diagnosis
04

In context

Pulmonary Arterial Hypertension Reclassified

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

Chinese Pulmonary Vascular Disease Research Group is the lead sponsor of 17 studies on the registry; 11 are open to participants now.

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult patients previously received chest X-rays, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS \& PUMC, Beijing, China.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old
  • Patients previously received chest X-ray, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS \& PUMC, Beijing, China

Exclusion criteria

Exclusion Criteria:

  • Patients without RHC
  • The quality of routine examinations and RHC cannot meet the requirement for further analysis
  • Severe loss of results of routine examinations (chest X-ray, electrocardiography, echocardiography, etc.)
06

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with pulmonary hypertension

    A series of routine examinations, including chest X-ray, electrocardiography, echocardiography, etc, would be performed on consecutive patients at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. An RHC with an mPAP of \>20 mmHg would confirm the diagnosis of PH. All these data will be collected as a source for machine learning or other artificial intelligence-assisted programs.

    Diagnostic Test: Right heart catheterization

  • Patients without pulmonary hypertension

    A series of routine examinations, including chest X-ray, electrocardiography, echocardiography, etc, would be performed on consecutive patients at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. An RHC with an mPAP of ≤20 mmHg would confirm the absence of PH. All these data will be collected as a source for machine learning or other artificial intelligence-assisted programs.

    Diagnostic Test: Right heart catheterization

Interventions

  • Diagnostic testRight heart catheterization

    RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).

07

What researchers measure

Primary outcomes

  1. Accuracy of diagnosis by artificial intelligence-assisted algorithm

    The investigators will calculate the area under the receiver operating characteristic curve of diagnosis by artificial intelligence-assisted algorithm and compare this index between artificial intelligence-assisted algorithm and RHC.

    Time frame: Baseline

Secondary outcomes

  1. Sensitivity of diagnosis by artificial intelligence algorithm

    The investigators will calculate the sensitivity of diagnosis by artificial intelligence-assisted algorithm and compare this index between artificial intelligence-assisted algorithm and RHC.

    Time frame: Baseline

  2. Specificity of diagnosis by artificial intelligence algorithm

    The investigators will calculate the sensitivity of diagnosis by artificial intelligence-assisted algorithm and compare this index between artificial intelligence-assisted algorithm and RHC.

    Time frame: Baseline

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Huang Z, Diao X, Huo Y, Zhao Z, Geng J, Zhao Q, Liu J, Xi Q, Xia Y, Xu O, Li X, Duan A, Zhang S, Gao L, Wang Y, Li S, Luo Q, Liu Z, Zhao W. Deep Learning-Enhanced Noninvasive Detection of Pulmonary Hypertension and Subtypes via Chest Radiographs, Validated by Catheterization. Chest. 2025 Nov;168(5):1215-1230. doi: 10.1016/j.chest.2025.06.008. Epub 2025 Jun 18. PubMed 40541737 ↗
  • Zhao W, Huang Z, Diao X, Yang Z, Zhao Z, Xia Y, Zhao Q, Sun Z, Xi Q, Huo Y, Xu O, Geng J, Li X, Duan A, Zhang S, Gao L, Wang Y, Li S, Luo Q, Liu Z. Development and validation of multimodal deep learning algorithms for detecting pulmonary hypertension. NPJ Digit Med. 2025 Apr 10;8(1):198. doi: 10.1038/s41746-025-01593-3. PubMed 40205021 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2022 (actual). Primary completion is estimated for Dec 2028, 78 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2025 → Dec 2028 and completion Dec 2025 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2022
First posted
Oct 4, 2022
StartActual
Jun 1, 2022
Primary completionEst.
Dec 31, 2028was Dec 2025
CompletionEst.
Dec 31, 2028was Dec 2025
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College · Beijing, China
Show 1 removed
  • Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College · Beijing, China
Oct 22, 2026
Primary completion
Dec 31, 2025→Dec 31, 2028
Oct 22, 2026
Study completion
Dec 31, 2025→Dec 31, 2028
Oct 22, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 40541737 ↗
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 40541737 ↗
    1 site added, 1 site removed
    Show site
    • Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College · Beijing, China
    Show 1 removed
    • Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College · Beijing, China
    Primary completion Dec 31, 2025→Dec 31, 2028
    Study completion Dec 31, 2025→Dec 31, 2028
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05566002
Lead sponsor
Chinese Pulmonary Vascular Disease Research Group
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Jun 1, 2022
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Zhihong Liu, MD, PhD
Contact
zhihongliufuwai@163.com
13269276067
Zhihong Liu, MD, PhD
principal investigator · Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion